[
    [
        {
            "time": "",
            "original_text": "大摩：上调上海医药(2607.HK)目标价至22港元 评级“增持”",
            "features": {
                "keywords": [
                    "大摩",
                    "上海医药",
                    "目标价",
                    "上调",
                    "增持"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "大摩：上调上海医药(2607.HK)目标价至22港元 评级“增持”",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "上海医药发布公告 子公司上药禾丰收国家药监局药品注册证书",
            "features": {
                "keywords": [
                    "上海医药",
                    "公告",
                    "子公司",
                    "上药禾丰",
                    "药品注册证书",
                    "国家药监局"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "上海医药发布公告 子公司上药禾丰收国家药监局药品注册证书",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "大摩：维持上海医药(02607)“增持”评级 目标价上调7%至22港元",
            "features": {
                "keywords": [
                    "大摩",
                    "上海医药",
                    "目标价",
                    "上调",
                    "7%",
                    "增持"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "大摩：维持上海医药(02607)“增持”评级 目标价上调7%至22港元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]